Analysts in the securities industry suggest paying attention to the clinical results to be released later this year by DongA ST's subsidiary, NeuroBo Pharmaceuticals (NeuroBo). On the 12th, Seo…

The dominance of the autoimmune disease treatment Humira (active ingredient: adalimumab), once the world's best-selling drug, is waning. Sandoz's biosimilar Hyrimoz has rapidly gained market share,…

“The GLP-1 obesity treatment market is expected to grow to 100 trillion won( approximately 77 billion dollars) by 2030. Including metabolic-associated steatohepatitis (MASH),…

A new treatment option for managing refractory blood cancer, specifically Diffuse Large B-Cell Lymphoma (DLBCL), has completed its approval process in Korea. This approval primarily…

The management dispute within Hanmi Pharmaceutical Group that has heated up the pharmaceutical and biotech industry for over 6months this year has come to an end. On the 10th, Lim Jong-yoon, an…

HK Inno.N Corporation is emerging as a company to watch in the second half of the year, following strong performance and promising U.S. clinical trial results. On the 9th, the securities industry…

Celltrion has announced that their biosimilar Omvoh (CT-P39), a treatment for allergic asthma and chronic idiopathic urticaria, has been approved by the UK's Medicines and Healthcare products…

Song Young-sook, chairwoman of Hanmi Pharm. Co., Ltd. has stepped down from the management of the company and said he will support a professional management system centred on Hanyang Precision…

The FDA approval of Eli Lilly's 'Donanemab' (marketed as Kisunla), the third Alzheimer's treatment globally, is anticipated to create a positive ripple effect for radiopharmaceutical companies…

ABL Bio has announced its ambition to become a global leader in the targeted cancer therapy market through the development of antibody-drug conjugates (ADCs) utilizing bispecific antibodies. On the…